Clinical experience in invasive fungal infections

Patrícia Pacheco1, Ana Sofia Ventura, Teresa Branco

  • 1Infectious Diseases Department, Hospital Prof. Dr. Fernando Fonseca, Amadora-Sintra, Portugal. patriciacorreiapacheco@gmail.com

Insights

Dual fungal lung infections by Aspergillus and Mucor are rare in AIDS patients. This case highlights the need for considering invasive fungi in immunocompromised individuals with risk factors.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pulmonology

Background:

  • Invasive filamentous fungal infections are uncommon in individuals with acquired immunodeficiency syndrome (AIDS).
  • Risk factors for these infections include profound immune suppression, hematologic malignancies, corticosteroid use, neutropenia, and chemotherapy.
  • Prompt diagnosis and treatment are crucial for managing these rare but severe conditions.

Observation:

  • A 34-year-old AIDS patient undergoing chemotherapy for oral plasmablastic lymphoma presented with low-grade fever and pulmonary cavitation.
  • Clinical presentation initially suggested tuberculosis, necessitating extensive diagnostic investigations.
  • The patient exhibited aggressive invasive fungal behavior in the lungs.

Findings:

  • A dual lung infection caused by Aspergillus and Mucor was diagnosed.
  • Treatment involved sequential administration of liposomal amphotericin B and posaconazole.
  • Histological examination of surgical specimens confirmed the presence of both Aspergillus and Mucor hyphae.

Implications:

  • This case underscores the importance of considering invasive filamentous fungal infections in immunocompromised patients, particularly those with AIDS and additional risk factors.
  • Aggressive fungal infections require a high index of suspicion and comprehensive diagnostic workup.
  • Multidisciplinary management, including antifungal therapy and potentially surgery, may be necessary for successful outcomes.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...